C4 Therapeutics Inc (CCCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 12,006 | 3,039 | 3,261 | 11,072 | 2,664 |
| Gross Profit | 12,006 | 3,039 | 3,261 | 11,072 | 2,664 |
| Operating Expenses | 33,448 | 35,258 | 40,688 | 38,880 | 40,232 |
| Operating Income | -21,442 | -32,219 | -37,427 | -27,808 | -37,568 |
| Interest Expense | -3,726 | -3,858 | 0 | 167 | 600 |
| Other Income | 0 | 0 | 2,950 | 1,941 | 2,246 |
| Pre-tax Income | -17,716 | -28,361 | -34,477 | -26,034 | -35,922 |
| Income Tax | N/A | N/A | 277 | 1,003 | N/A |
| Net Income Continuous | -17,716 | -28,361 | -34,754 | -27,037 | -35,922 |
| Net Income | $-17,716 | $-28,361 | $-34,754 | $-27,037 | $-35,922 |
| EPS Basic Total Ops | -0.26 | -0.41 | -0.68 | -0.55 | -0.73 |
| EPS Basic Continuous Ops | -0.26 | -0.41 | -0.68 | -0.55 | -0.73 |
| EPS Diluted Total Ops | -0.26 | -0.41 | -0.68 | -0.55 | -0.73 |
| EPS Diluted Continuous Ops | -0.26 | -0.41 | -0.68 | -0.55 | -0.73 |
| EPS Diluted Before Non-Recurring Items | -0.26 | -0.41 | -0.68 | N/A | N/A |
| EBITDA(a) | $-22,659 | $-33,036 | $-37,964 | $-28,403 | $-38,010 |